A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB)

Updated 06/21/2024

Status Completed

Clinical Trial Summary

Outpatients with at least one dispensing record of any medication will be included in the study. An index date will be assigned to each participant and prescription records for anticholinergics will be used in the study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03903094
Study type	Observational
Source	Astellas Pharma Inc
Contact
Status	Completed
Phase
Start date	March 7, 2019
Completion date	May 6, 2022

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00507169` - SVT-40776 in Patients Suffering From Overactive Bladder Syndrome	Phase 2
	Completed	`NCT02216214` - Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)	Phase 4
	Completed	`NCT02294396` - Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.	Phase 4
	Completed	`NCT01936870` - Drug Use Investigation for Toviaz
	Completed	`NCT03846895` - Vaginal CO2 Laser in Postmenopausal Women With Overactive Bladder Syndrome (OAB)	N/A
	Terminated	`NCT04451382` - PTNS vs Botox of Refractory OAB
	Terminated	`NCT04641975` - A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)	Phase 3
	Completed	`NCT00366002` - Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder	Phase 4
	Completed	`NCT02138747` - A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)	Phase 4
	Completed	`NCT03602508` - Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
	Completed	`NCT03572231` - A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
	Completed	`NCT05211193` - Open Label Study to Evaluate the Efficacy of the Home Based Electrical Transcutaneous URIS I in the Treatment of Overactive Bladder (OAB).
	Completed	`NCT04562090` - A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder	Phase 4
	Completed	`NCT00282932` - Detrol LA In Men With Overactive Bladder.	Phase 4
	Completed	`NCT01639794` - Vesitirim™ in Men Postmarketing Observational Study	N/A
	Withdrawn	`NCT01317810` - A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication	N/A
	Completed	`NCT00742833` - A Phase II Study of KUC-7483 in Patients With Overactive Bladder	Phase 2